Stockscreener 앱 받기
727.21
2.11%
-15.70
시간 외 거래:
726.50
-0.71
-0.10%
Lilly Eli Co 주식(LLY)의 최신 뉴스
FDA Tightens Grip On Safe Weight Loss Drugs, WHO Adds Them To Essential Medicines List - Benzinga
No more needles — a weight-loss pill is on its way to Britain - The Times
Lilly, Novo Sink on FDA List of Foreign GLP-1 Manufacturers - MSN
Lilly, Novo Sink on FDA List of Foreign GLP-1 Ingredient Makers - Bloomberg.com
Advanced analytics toolkit walkthrough for Eli Lilly and Company2025 Institutional Moves & Daily Stock Momentum Reports - Newser
Eli Lilly (LLY) Faces FDA Crackdown on Compounded GLP-1 Drugs - GuruFocus
Eli Lilly and Company Stock (LLY) Opinions on Recent Drug Trial Results - Quiver Quantitative
Lila Biologics, Eli Lilly partner for radioligand therapies - Mobi Health News
Lila Biologics, Eli Lilly team up for radioligand therapies - Mobi Health News
Eli Lilly Will Soon Ask Regulators To Approve Its Weight-Loss Pill. Is It Now A Buy? - Investor's Business Daily
Eli Lilly’s (LLY) Lung Cancer Drug Given ‘Breakthrough Therapy’ Designation - TipRanks
Is Eli Lilly Stock a Buy After Gaining 5% in 1 Day? - The Motley Fool
Lilly-Merck Combo Drug For Lung Cancer Receives FDA Breakthrough StatusEli Lilly (NYSE:LLY) - Benzinga
Eli Lilly (LLY) Gains Breakthrough Therapy Designation For Advanced Lung Cancer Treatment - simplywall.st
Lila Biologics Spins Out of Baker Lab, Announces Lilly Collaboration - Inside Precision Medicine
Startup spun out of Nobel Laureate’s lab teams with Eli Lilly to fight cancer with AI - GeekWire
Type 1 Diabetes Pipeline 2025: Comprehensive Clinical Trials and Therapies Analysis with Key MOA and ROA Insights by DelveInsight | Eli Lilly and Company, Regor Pharma, AstraZeneca, Eccogene, Pfizer - Barchart.com
FDA grants breakthrough therapy designation to Lilly’s lung cancer drug - Investing.com
Lilly's olomorasib receives U.S. FDA's Breakthrough Therapy designation for the treatment of certain newly diagnosed metastatic KRAS G12C-mutant lung cancers - Eli Lilly
FDA Fast-Tracks Revolutionary Lung Cancer Drug: Lilly's Olomorasib Shows Promise in Advanced NSCLC Treatment - Stock Titan
Zacks Investment Ideas feature highlights: Church & Dwight, Eli Lilly and Viatris - sharewise.com
Where Will Eli Lilly Be in 3 Years? - The Motley Fool
Eli Lilly Wins Fresh Bullish Call From BMO - TradingView
Global drugmakers rush to boost US presence as tariff threat looms - Reuters
Hims & Hers gains after court rejects Eli Lilly’s case against Willow - Yahoo Finance
After Copycat Boom, China's Drugmakers Target Global Generics - Benzinga
BMO Capital Markets Reaffirms ‘Buy Rating’ on Eli Lilly Stock (LLY) - TipRanks
Gastric Cancer Pipeline 2025: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight | Eli Lilly and Company, BeiGene, Hutchison MediPharma, Astellas Pharma, Henlix - Barchart.com
PRESSR: Lilly's oral GLP-1, orforglipron, is successful in third Phase 3 trial, triggering global regulatory submissions this year for the treatment of obesity - TradingView
Stomach Cancer Treatment Market Review 2020-2024 and Forecast 2025-2030 - GlobeNewswire Inc.
Fueled by Lilly's Lebanon investment, local builds future in biotech at Ivy Tech - reporter.net
Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Analyst Forecasts $25 Billion of Annual Sales for Eli Lilly’s (LLY) New Weight-Loss Pill - TipRanks
Eli Lilly's once-daily obesity pill passes phase 3 trials - 조선일보
BMO Capital Affirms Eli Lilly (LLY)’s ‘Outperform’ Rating on Weight Loss Drug Prospects - Yahoo Finance
Eli Lilly's New Drugs Beyond Mounjaro And Zepbound Boost Sales - Barchart.com
Eli Lilly's New Drugs Beyond Mounjaro and Zepbound Boost Sales - The Globe and Mail
What's Going On With Novo Nordisk Stock Tuesday?Novo Nordisk (NYSE:NVO), Eli Lilly (NYSE:LLY) - Benzinga
Eyes on Asia: Lilly, Fosun, RemeGene - BioXconomy
Lilly Ends Two Mid-Stage Trials for Second Obesity Asset - BioSpace
Is Eli Lilly and Company’s growth already priced inJuly 2025 Decliners & Fast Moving Stock Watchlists - خودرو بانک
Eli Lilly & Co: Strong Buy Rating Driven by Promising Weight Loss Drug and Innovative Subscription Model - TipRanks
Recently, Eli Lilly's obesity treatment "Munzaro" has been released in Korea and interest in obesity.. - 매일경제
Recently, Eli Lilly's obesity treatment Maunzaro was released in Korea, and as interest in obesity t.. - 매일경제
Eli Lilly and Company (LLY) Halts UK Mounjaro Shipments Ahead of Planned Price Increase - uk.finance.yahoo.com
Can trapped investors hope for a rebound in Eli Lilly and CompanyTrade Performance Summary & Detailed Earnings Play Alerts - Newser
Eli Lilly’s SWOT analysis: stock’s growth potential in obesity market faces challenges - Investing.com
Eli Lilly (LLY) Partners with JD.com to Sell Weight-Loss Drugs in China - TipRanks
ESC25: Novo's Wegovy slashes CV risk by 57% over Lilly's Zepbound in real-world study - FirstWord Pharma
Novo Nordisk Says Wegovy Cuts Heart Risk by 57% Compared With Eli Lilly’s Obesity Drug - The Wall Street Journal
Eli Lilly and Company Stock (LLY) Opinions on Orforglipron Trial Data | LLY Stock News - Quiver Quantitative
Can you recover from losses in Eli Lilly and CompanyJuly 2025 Levels & Verified Chart Pattern Trade Signals - Newser
HSBC Upgrades Eli Lilly (LLY) to Hold, Lifts Price Target to $700 - Yahoo Finance
0.18%
1.02%
자본화:
|
볼륨(24시간):